Skip to main content
TipRanks
Go Ultimate75% OFF

Inhibikase Therapeutics (IQT0) AI Stock Analysis

1 Followers
DE:IQT0

Inhibikase Therapeutics

(Munich:IQT0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low leverage and strengthened equity baseEffectively zero debt reduces solvency and interest-burden risk while the expanded equity base provides financial support for clinical development. This gives Inhibikase greater flexibility to fund operations and pursue its lead program without the constraints associated with heavy leverage.
Negative Factors
Pre-revenue business modelWith no reported product revenue, Inhibikase remains dependent on financing while it advances clinical candidates. The absence of recurring operating revenue means commercial progress is still contingent on successful development and approval, leaving the business exposed to execution risk.

Inhibikase Therapeutics (IQT0) vs. iShares MSCI Germany ETF (EWG)

-5%0%5%10%15%20%DE:IQT00.00%EWG+9.26%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 203.39M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-3.3
Beta (1Y)
―
Revenue Growth
―
EPS Growth
32.42%
Country
Germany
Employees
35
Sector
General
Sector Strength
55
Industry
Biotechnology

Inhibikase Therapeutics Business Overview & Revenue Model

Company Description

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threaten...

Inhibikase Therapeutics Earnings Call Summary

Earnings Call Date:Aug 14, 2024(Q2-2024)|% Change Since:104.92%|Next Earnings Date:May 17, 2021
Earnings Call SentimentNeutral

The earnings call presented a mix of positive developments, such as the completion of trial enrollments and financial strengthening, alongside challenges like observed adverse events and increased expenses. The potential for significant advancements, particularly in PAH and Parkinson's disease treatments, is promising, though tempered by some operational hurdles.

Positive Updates

Completion of Phase II 201 Trial Enrollment
Inhibikase Therapeutics has completed enrollment for the Phase II 201 Trial for risvodetinib in Parkinson's disease, marking a significant milestone. Top line data from the trial is expected in November.

Negative Updates

Adverse Events in Phase II 201 Trial
In the Phase II 201 Trial, 41 mild and 8 moderate adverse events were observed that may be related to risvodetinib treatment, with 6 participants withdrawing from the trial.

Company Guidance

During the Inhibikase Therapeutics Q2 2024 earnings call, executives highlighted several key metrics and developments. The company completed enrollment for the Phase II trial of risvodetinib in Parkinson's disease, expecting to report top-line data in November. They observed 49 adverse events and had six withdrawals from the trial. For their IkT-001Pro, a prodrug formulation aimed at pulmonary arterial hypertension (PAH), they filed an IND on August 9, 2024, with plans for a Phase IIb trial involving around 100 patients. Financially, Inhibikase reported a net loss of $5.0 million for the quarter, with R&D expenses decreasing by $1.5 million to $3.1 million, and a cash position of $7.9 million as of June 30, 2024. The company expects its cash runway to extend into December 2024, bolstered by raising $4 million in May from registered direct offering and concurrent private placement.

Inhibikase Therapeutics Risk Analysis

Inhibikase Therapeutics disclosed 82 risk factors in its most recent earnings report. Inhibikase Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.Changing U.S. legal and regulatory restrictions on relationships with China-based biotechnology companies could restrict our business relationships, increase our compliance costs, and adversely affect our business.Q3, 2026

Inhibikase Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:IQT0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SRZNSRZN53Neutral$616.07M-0.75228.00%―192.12%-100.54%
ANIXANIX49Neutral$88.65M-8.44-70.44%――10.04%
SPROSPRO44Neutral$55.14M-1.92-75.22%―36.15%38.57%
ATOSATOS43Neutral$19.26M-0.52-117.07%――-10.80%
TCRXTCRX38Underperform$9.83M-0.17-140.75%―-38.43%20.89%

* General Sector Average

Performance Comparison

-50%0%50%100%150%DE:IQT0ATOSANIXSPROSRZNTCRXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:IQT0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:IQT0Inhibikase Therapeutics, Inc.2.500.000.00%
ATOSAtossa Therapeutics, Inc.1.93-9.52-83.15%
ANIXAnixa Biosciences2.55-1.80-41.38%
SPROSpero Therapeutics0.95-1.43-60.25%
SRZNSurrozen, Inc.32.3218.82139.41%
TCRXTscan Therapeutics, Inc.0.14-0.89-85.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.